摘要:
The invention provides CD3 specific binding molecules and nucleic acid sequences encoding said CD3 specific binding molecules. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and compositions comprising said construct. The invention also provides the use of said constructs for the preparation of pharmacutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
摘要:
The invention provides immunogenicity-reduced antibodies or antibody fragments that bind a human CR1 receptor. The immunogenicity-reduced anti-CR1 antibody of the invention comprises one or more non-human sequences modified to comprise one or more amino acid substitutions so that the immunogenicity-reduced antibody id non-immunogenic or less immunogenic to a human. The invention also provides bispecific molecules comprising such an immunogenicity-reduced anti-CR1 antibody and an antigen-recognition portion that binds a pathogen. The invention further provides methods and compositions for the treatment of diseases or disorders caused by a blood-borne immunogenic pathogen using the bispecific molecule the invention of the invention.
摘要:
Antibodies or functional antibody fragments that recognize or interfere with the production of a component of the CD3 antigen complex are de-immunized.
摘要:
The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
摘要:
The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
摘要:
The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.
摘要:
The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.
摘要:
A target protein is rendered less immunogenic to a given species by (a) determining at least part of the amino acid sequence of the target protein; (b) identifying in the amino acid sequence one or more potential epitopes for T-cells (“T-cell epitopes”) of the given species; and (c) modifying the amino acid sequence to eliminate at least one of the T-cell epitopes identified in step (b) to reduce the immunogenicity of the protein when exposed to the immune system of the given species.
摘要:
The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
摘要:
This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.